Physician profile
Robert Sholomon
NPI 1679591044
$720.75
in general payments reported to CMS, 2019-2025
11 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $96.71 · 2021: $62.34 · 2022: $27.68 · 2023: $16.04 · 2024: $31.48 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $182.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $177.92 | 2019-2025 | Precision 1 |
| Shire North American Group INC | $127.60 | 2019 | |
| Maculogix, INC. | $87.27 | 2019-2020 | |
| Allergan, INC. | $81.77 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $50.07 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $49.93 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $47.92 | 2024-2025 | Xdemvy |
| Alcon Research LLC | $37.56 | 2019 | |
| Oyster Point Pharma, INC. | $27.68 | 2022 | |
| Bausch & Lomb Americas INC. | $16.99 | 2025 | Miebo |
| Abbvie INC. | $16.04 | 2023 | Lumigan, Alphagan P, Vuity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sholomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.